Latest Headlines

  1. AbbVie And Iambic Announce Collaboration To Accelerate AI-Driven Drug Discovery 9/21/2026
  2. Iambic Launches Enchant v3 – Molecular Superintelligence Designed To Advance End-To-End Drug Discovery & Development 9/21/2026

    Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today unveiled Enchant v3, the next generation of its multimodal transformer model built to advance end-to-end drug discovery and development.

  3. Emulate Enters Final Stage Of FDA ISTAND Program For Human Liver-Chip With Submission Of Qualification Package Covering Both Zoë® And AVA™ Organ-Chip Platforms 9/18/2026

    Emulate, Inc., the leading provider of next-generation Organ-on-a-Chip technology, today announced it has submitted its FDA Innovative Science and Technology Approaches for New Drugs (ISTAND) full qualification package (FQP) for its Human Liver-Chip, advancing the company’s efforts to establish Organ-on-a-Chip technology as a qualified Drug Development Tool (DDT) for drug-induced liver injury (DILI) assessment.

  4. Niagen Bioscience Engages Veteran Pharmaceutical Executives And Biotechnology Experts To Support Drug Development Program And Strategic Business Growth 9/17/2026

    Niagen Bioscience, Inc., the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug candidate, targeting rare genetic diseases and aging-related disorders.

  5. Xenon Announces Azetukalner NDA Submission To FDA For Focal Seizures And Provides Update On Psychiatry Clinical Program 9/17/2026

    Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it has submitted a New Drug Application (NDA) for azetukalner in focal seizures (FS) to the U.S. Food and Drug Administration (FDA).

  6. Twist Bioscience Joins Lilly Tunelab To Advance Antibody Drug Discovery 9/16/2026

    Twist Bioscience Corporation, a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly).

  7. Novo And Anthropic Will Collaborate To Advance Drug Discovery With Claude 9/16/2026

    Novo Nordisk and Anthropic today announced a collaboration that will help Novo accelerate the development of new medicines and advance AI-driven software development.

  8. IASO Bio's CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance 9/16/2026

    IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignancies and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for IASO208, the Company's proprietary CD20-targeted in vivo CAR-T therapy developed using its InTelliCAR™ platform.

  9. GATC Health Joins Critical Path Institute's New Approach Methodologies Developer Coalition To Advance AI-Enabled Regulatory Science 9/14/2026

    GATC Health Corp (“GATC”), a tech-bio company applying artificial intelligence and multiomics to accelerate drug discovery and development, today announced that it has joined the Critical Path Institute’s® (C-Path) New Approach Methodologies Developer Coalition (NAMs-DC), a precompetitive coalition working to advance the adoption, validation and qualification of new approach methodologies (NAMs) for drug discovery and development.

  10. FDA Approves Telix's Brain Cancer Imaging Drug Pixclara 9/14/2026

    Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).